IL1B and metabolic dysfunction-associated steatotic liver disease: It was found that the expressions of IL-10, IL-6, IL-1β, MCP-1, IL-18, and TNF-α of the NAFLD group increased markedly, while these were inhibited after SLBZS administration, except for IL-1β (Figures 2H–N).